- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-1-1-mer
- Ligands
- 22 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.11: 10 residues within 4Å:- Chain A: E.206, V.249, L.256, N.257, N.371, C.372, G.373, V.439, S.440
- Ligands: NAG-NAG.10
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:G.373
NAG-NAG-BMA-MAN-MAN.21: 7 residues within 4Å:- Chain D: P.207, V.249, L.256, N.257, V.439, S.440
- Ligands: NAG-NAG.26
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.27: 12 residues within 4Å:- Chain D: T.129, Q.131, S.151, F.152, N.153
- Chain G: Y.80, N.81, Y.82
- Chain H: D.124, R.126, Y.131, Y.139
1 PLIP interactions:1 interactions with chain H- Hydrophobic interactions: H:D.124
- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-6)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN.28: 13 residues within 4Å:- Chain D: V.135, T.136, N.149, Y.166, D.315
- Chain H: Y.73, D.74, R.92, D.93, N.94, S.95, F.134, W.135
4 PLIP interactions:2 interactions with chain H, 2 interactions with chain D- Hydrophobic interactions: H:F.134, H:W.135, D:Y.166
- Hydrogen bonds: D:Y.166
- 28 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.29: 2 residues within 4Å:- Chain A: E.88, N.89
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain A: T.136, N.138
Ligand excluded by PLIPNAG.31: 4 residues within 4Å:- Chain A: R.344, F.347, G.348, N.349
Ligand excluded by PLIPNAG.32: 4 residues within 4Å:- Chain A: N.271, I.272, T.273, N.274
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain A: N.134, R.144, G.145
Ligand excluded by PLIPNAG.34: 4 residues within 4Å:- Chain B: T.133, N.134, R.144, K.148
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain B: Q.288, N.290, N.326
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain B: N.349
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain B: N.271, T.273
Ligand excluded by PLIPNAG.38: 4 residues within 4Å:- Chain B: K.227, F.228, N.229, T.231
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain B: N.296, I.317, V.435
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain B: E.88, N.89
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain C: N.100, S.101
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain C: N.107, S.109, E.110
Ligand excluded by PLIPNAG.43: 5 residues within 4Å:- Chain C: K.122, E.123, S.125, N.126, Y.127
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain D: N.134, K.148
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain D: N.271, T.273
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain D: Q.288, N.290, N.326
Ligand excluded by PLIPNAG.47: 1 residues within 4Å:- Chain D: N.349
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain D: S.453, T.454, N.455
Ligand excluded by PLIPNAG.49: 2 residues within 4Å:- Chain D: N.89
- Chain E: S.17
Ligand excluded by PLIPNAG.50: 7 residues within 4Å:- Chain D: D.225, K.227, F.228, N.229, G.230, T.231, R.268
Ligand excluded by PLIPNAG.51: 3 residues within 4Å:- Chain E: N.100, S.101, S.102
Ligand excluded by PLIPNAG.52: 3 residues within 4Å:- Chain E: N.107, S.109, E.110
Ligand excluded by PLIPNAG.53: 3 residues within 4Å:- Chain E: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.54: 2 residues within 4Å:- Chain F: N.100, S.102
Ligand excluded by PLIPNAG.55: 2 residues within 4Å:- Chain F: N.107, E.110
Ligand excluded by PLIPNAG.56: 5 residues within 4Å:- Chain F: E.123, I.124, S.125, N.126, Y.127
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Willis, J.R. et al., Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Immunity (2022)
- Release Date
- 2022-09-28
- Peptides
- HIV Envelope ApexGT3 gp120: ABD
HIV Envelope ApexGT3 gp41: CEF
PG9.iGL Fab Light Chain: G
PG9.iGL Fab Heavy Chain: H - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
CD
EC
DE
FF
BG
LH
H
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-1-1-mer
- Ligands
- 22 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-6)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 28 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Willis, J.R. et al., Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Immunity (2022)
- Release Date
- 2022-09-28
- Peptides
- HIV Envelope ApexGT3 gp120: ABD
HIV Envelope ApexGT3 gp41: CEF
PG9.iGL Fab Light Chain: G
PG9.iGL Fab Heavy Chain: H - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
CD
EC
DE
FF
BG
LH
H